Author

Ou Jiang

Institution: The First People's Hospital of Neijiang

Observed institution: The First People's Hospital of Neijiang

ORCID: 0000-0002-1971-0534

Observed ORCID: 0000-0002-1971-0534

OpenAlex ID: A5037165306

Sprayable coating based on fluorinated silica nanocomposites with superhydrophobic and antibacterial properties for advanced concrete

2022 · Feng Yang, Wuyifan Zhou, et al. · Progress in Natural Science Materials International · 33

Finotonlimab (PD-1 inhibitor) plus bevacizumab (bevacizumab biosimilar) as first-tier therapy for late-stage hepatocellular carcinoma: a randomized phase 2/3 trial

2025 · Chuanhua Zhao, Yanqiao Zhang, et al. · Signal Transduction and Targeted Therapy · 27

Results of a phase 1/2 study of MHB088C: A novel B7H3 antibody-drug conjugate (ADC) incorporating a potent DNA topoisomerase I inhibitor in recurrent or metastatic solid tumors.

2024 · Lin Shen, Caicun Zhou, et al. · Journal of Clinical Oncology · 16

Combination of radiotherapy and ICIs in advanced hepatocellular carcinoma: A systematic review of current evidence and future prospects (Review)

2025 · Cheng Ma, Xinlin Yu, et al. · Oncology Letters · 11

Construction of Superhydrophobic Coating on Iron Surface with Enhanced Anti-Corrosion, Anti-Adhesive and Anti-Bacterial Properties

2022 · Wuyifan Zhou, Feng Yang, et al. · Materials · 6

Efficacy, safety and biomarkers of SG001 for patients with previously treated recurrent or metastatic cervical cancer: an open‐label, multicenter, phase Ib trial

2024 · Jing Zuo, Wei Duan, et al. · 癌症：英文版 · 3

Results of a phase 1/2 study of MHB036C: A potential best-in-class TROP2 antibody-drug conjugate (ADC) incorporating a potent DNA topoisomerase I inhibitor in locally advanced or metastatic solid tumors.

2024 · Shun Lu, Qingyuan Zhang, et al. · Journal of Clinical Oncology · 3

Comparative efficacy and safety of immune checkpoint inhibitor–based strategies in advanced hepatocellular carcinoma: a systematic review and network meta-analysis

2025 · Xinlin Yu, Xialin Zhang, et al. · International Journal of Surgery · 2

Safety and efficacy of QLC5508 (MHB088C) in heavily-treated patients with metastatic castration-resistant prostate cancer: Updated data from a phase 1/2 trial.

2026 · Xinan Sheng, Yuping Sun, et al. · Journal of Clinical Oncology · 1

Phase 1b Multicenter Study of SG001, a Humanized Anti-PD-1 Antibody, in Patients with Advanced Solid Tumors

2025 · Jian Fang, Ou Jiang, et al. · Drug Design Development and Therapy · 1

Preliminary results of ZG005, a bispecific antibody targeting PD-1 and TIGIT, as monotherapy in patients with advanced cervical cancer.

2025 · Hanmei Lou, Shuxia Cheng, et al. · Journal of Clinical Oncology · 1

Preliminary results from a phase I expansion study of ZG005, a bispecific antibody targeting TIGIT and PD-1, as monotherapy in patients with advanced solid tumors.

2024 · Shukui Qin, Ying Cheng, et al. · Journal of Clinical Oncology · 1

Comparing the efficacy of immune checkpoint inhibitors with and without microwave ablation in advanced hepatocellular carcinoma in real‑world clinical practice: A retrospective cohort study

2026 · Chun Wei, Sizhong Chen, et al. · Oncology Letters

Works count: 13

Citation count: 105

H-index: 5

I10-index: 4